ADAP_OUT_1 [2025-04-29 09:03:53 -0400] 5884 Bytes | 1644 tokens | Cum: 1644 tkns (20.55% of 8k)
==========================================================================

Sensor readings are abnormal, Captain. Adaptimmune Therapeutics (ADAP) rising sharply—from $0.2653 to $0.2899. It is now 9:03 AM on Tue Apr 29, 2025. Recommend deeper scan before action is taken.

--- COMPANY PROFILE ---
Company: Adaptimmune Therapeutics (ADAP)
IPO: 2015-05-06 (9 Years Ago)
Market Cap: $72,590,854
Shares Outstanding: 1,543,390,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Here’s a list of headlines for Adaptimmune Therapeutics:

Mar-21-25 12:05PM - Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
Mar-21-25 12:05PM 03:01AM - Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
Mar-20-25 12:10PM - Adaptimmune targets $400M sarcoma franchise peak sales by 2027
Mar-20-25 12:10PM 12:10PM - Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Mar-20-25 12:10PM 07:00AM - Adaptimmune Provides Q4 and Full Year 2024 Business Update
Mar-19-25 06:00PM - Here's the major earnings before the open tomorrow
Mar-18-25 07:00AM - From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
Mar-12-25 04:54PM - Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Jan-30-25 04:00PM - Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Jan-13-25 08:00AM - Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Dec-19-24 07:30AM - Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Dec-02-24 04:00PM - First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Nov-15-24 05:00AM - Halozyme bids for Evotec; BeiGene gets a new name
Nov-14-24 11:55AM - Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Nov-14-24 11:55AM 02:15AM - Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...
Nov-13-24 04:05PM - Adaptimmune Reports Q3 2024 Financial and Business Updates
Nov-13-24 04:05PM 09:00AM - Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Nov-05-24 09:19AM - Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Oct-31-24 05:20PM - Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Sep-20-24 08:35AM - Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Sep-16-24 12:07PM - Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Aug-28-24 08:00AM - Adaptimmune to Participate in Two Bank Conferences this September

Prior AI Reports for ADAP:
1. 2025-04-03 – Score: 54 – Target: 0.4900 – Highs: 0.3301 / 0.3200 / 0.28
sales-surge-amidst-performance-plunge-a-paradox-unfolds
2. 2025-04-02 – Score: 60 – Target: 0.3200 – Highs: 0.3224 / 0.3301 / 0.32
high-sales-growth-amidst-financial-instability-sparks-investor-interest

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-25T18:00:00Z - LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight
B2 - 2024-07-04T02:06:38Z - Biotechnology acquisitions could impact FDA decisions to watch in Q3 By Proactive Investors - Investing.com Australia
B3 - 2024-04-15T18:12:00Z - Adaptimmune (ADAP) Down on End of Collaboration With Roche
B4 - 2024-03-08T18:47:01Z - Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B5 - 2024-03-08T15:08:32Z - Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
B6 - 2024-02-13T23:15:08Z - Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Adaptimmune Therapeutics (ADAP).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ADAP_OUT_3 [2025-04-29 09:03:54 -0400] 640 Bytes | 174 tokens | Cum: 1820 tkns (22.75% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Adaptimmune (ADAP) Down on End of Collaboration With Roche**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2255611/adaptimmune-adap-down-on-end-of-collaboration-with-rocheAdaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_5 [2025-04-29 09:03:55 -0400] 971 Bytes | 277 tokens | Cum: 2099 tkns (26.24% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T10:33:46Z - Long Focus Capital Management LLC Increases Stock Position in Adaptimmune Therapeutics plc (NASDAQ:A...
A2 - 2025-04-23T21:05:54Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Candel Therapeutics (NASDAQ:CADL)...
A3 - 2025-04-23T06:09:33Z - Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated at StockNews.com...
A4 - 2025-04-15T05:13:25Z - Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com...
A5 - 2025-04-07T06:14:05Z - Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ADAP_OUT_7 [2025-04-29 09:03:56 -0400] 1181 Bytes | 306 tokens | Cum: 2407 tkns (30.09% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Long Focus Capital Management LLC Increases Stock Position in Adaptimmune Therapeutics plc (NASDAQ:ADAP)**Date: 2025-04-25Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/long-focus-capital-management-llc-increases-stock-position-in-adaptimmune-therapeutics-plc-nasdaqadap-2025-04-23/Long Focus Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 54.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,494,393 shares of the biotechnology company's stock after buying an additional 7,194,503 shares during the quarter. Long Focus Capital Management LLC owned approximately 8.01% of Adaptimmune Therapeutics worth $11,040,000 at the end of the most recent reporting period.

Other institutional

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_9 [2025-04-29 09:03:57 -0400] 1181 Bytes | 285 tokens | Cum: 2694 tkns (33.67% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its position in shares of Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock valued at $1,361,000 after acquiring an additional 869,949 shares during the period. Rock Springs Capital Management LP grew its holdings in Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after purchasing an additional 58,000 shares during the period. LPL Financial LLC increased its position in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after buyin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_11 [2025-04-29 09:03:58 -0400] 1181 Bytes | 295 tokens | Cum: 2991 tkns (37.39% of 8k)
==========================================================================

Showing A1 (chunk 3 of 7): g an additional 94,623 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company's stock worth $166,000 after buying an additional 98,581 shares during the period. Finally, Virtu Financial LLC lifted its position in shares of Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after buying an additional 21,688 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company's stock.

ADAP has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_13 [2025-04-29 09:03:59 -0400] 1181 Bytes | 295 tokens | Cum: 3288 tkns (41.10% of 8k)
==========================================================================

Showing A1 (chunk 4 of 7): report on Friday, March 21st. Scotiabank lowered their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a report on Friday, March 21st. StockNews.com initiated coverage on Adaptimmune Therapeutics in a research note on Tuesday. They set a "buy" rating for the company. Jones Trading downgraded Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Finally, Guggenheim dropped their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price targ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_15 [2025-04-29 09:04:00 -0400] 1181 Bytes | 338 tokens | Cum: 3628 tkns (45.35% of 8k)
==========================================================================

Showing A1 (chunk 5 of 7): et of $1.83.

View Our Latest Research Report on ADAP

NASDAQ:ADAP opened at $0.26 on Wednesday. The stock has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.57. The stock has a market cap of $67.47 million, a PE ratio of -1.19 and a beta of 2.84. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics plc has a one year low of $0.20 and a one year high of $1.48.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $3.22 million for the quarter, compared to analysts' expecta

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_17 [2025-04-29 09:04:00 -0400] 1181 Bytes | 275 tokens | Cum: 3905 tkns (48.81% of 8k)
==========================================================================

Showing A1 (chunk 6 of 7): tions of $16.56 million. Equities research analysts expect that Adaptimmune Therapeutics plc will post -0.14 EPS for the current fiscal year.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please sen

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_19 [2025-04-29 09:04:01 -0400] 927 Bytes | 204 tokens | Cum: 4111 tkns (51.39% of 8k)
==========================================================================

Showing A1 (chunk 7 of 7): d any questions or comments about this story to [email protected].

Before you consider Adaptimmune Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.

While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_21 [2025-04-29 09:04:02 -0400] 1103 Bytes | 277 tokens | Cum: 4392 tkns (54.90% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-24 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related not...

S2 - 2025-03-24 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 24, 2025, Adaptimmune Therapeutics plc (the Company and collectively with any Company affiliates that are made party to the Loan Agrmt, Borrower) entered into an amendment (Amendment) to the Loan and Security Ag...

S3 - 2025-03-24 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 24, 2025, Adaptimmune Therapeutics plc (the Company and collectively with any Company affiliates that are made party to the Loan Agrmt, Borrower) entered into an amendment (Amendment) to the Loan and Security Ag...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADAP_OUT_23 [2025-04-29 09:04:03 -0400] 1181 Bytes | 236 tokens | Cum: 4630 tkns (57.88% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report. In addition to our historical consolidated financial information, the following discussion contains

forward-looking statements that reflect our plans, estimates, beliefs and expectations. Our actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Part I, Item 1A. Risk Factors.

Overview

We are a commercial-stage biopharmaceutical compa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_25 [2025-04-29 09:04:04 -0400] 1181 Bytes | 281 tokens | Cum: 4913 tkns (61.41% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ny working to redefine the treatment of solid tumor cancers with cell therapies. With the approval by the U.S. Food and Drug Administration (FDA) of our first biologics license application (BLA) for TECELRA, which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S., we are now focused on its launch and commercialization.

We are planning commercial launch for our second T-cell immunotherapy, lete-cel, for people with synovial sarcoma and myxoid liposarcoma in 2026. This product will significantly expand our treatable patient population within our commercial sarcoma franchise with up to $400 million annual peak combined US sales from TECELRA and lete-cel. We estimate that approximately 400 newly diagnosed patients per year are biomarker eligible for TECELRA, and an incremental 600 newly diagnosed synovial sarcoma and myxoid liposarcoma pa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_27 [2025-04-29 09:04:05 -0400] 1181 Bytes | 269 tokens | Cum: 5184 tkns (64.80% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): tients per year in the US will be biomarker eligible for lete-cel.

In addition to our commercial sarcoma franchise we remain committed to our collaboration with Galapagos which uses our uza-cel candidate manufactured using the Galapagos manufacturing process. A clinical trial authorization to start a Phase 1 trial in head and neck cancer is planned for 2025.

During the fourth quarter of 2024 we announced that we were ceasing further investment in all non-core programs. We are undertaking a reduction in headcount of approximately 29% and a reduction of total operating expenses of approximately 25% (as compared to 2024 operating expenses). As of the end of February 2025, the majority of the headcount reduction has been completed. As part of this restructuring in December 2024, we also announced changes to our executive leadership team. In addition, we are implementing additional cost red

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_29 [2025-04-29 09:04:06 -0400] 1181 Bytes | 285 tokens | Cum: 5471 tkns (68.39% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): uction for our preclinical PRAME and CD70 programs and are evaluating all strategic options to maximize shareholder value.

TECELRA and Commercialization

We are focused on the commercialization of TECELRA for the treatment of advanced synovial sarcoma and for which we received FDA approval on August 1, 2024. As of March 18, 2025, 20 ATCs are available to initiate the treatment journey for our patients and ten patients have been apheresed. We are confident that our full network of approximately 30 ATCs will be active by the end of 2025, covering an estimated 80% of patients treated in sarcoma centers of excellence. Companion diagnostics for biomarker detection are approved and available and we have adequate manufacturing capacity to meet orders. AdaptimmuneAssist is available to support our patients and HCPs.

Letetresgene autoleucel (lete-cel)

Lete-cel targets the NY-ESO antigen and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_31 [2025-04-29 09:04:06 -0400] 1181 Bytes | 325 tokens | Cum: 5798 tkns (72.47% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): has been in clinical trials (the IGNYTE-ESO trial) for people with synovial sarcoma and myxoid round cell liposarcoma (myxoid liposarcoma). It is the second product in our sarcoma franchise. Final data for the IGNYTE-ESO trial were reported at the Connective Tissue Oncology Society Annual Meeting (CTOS) in November 2024.

In January 2025, lete-cel was granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid liposarcoma who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.

Clinical Programs

During 2025 we anticipate filing an IND for ADP-5701 for a Phase 1 trial in Head and Neck Cancer in collaboration with Galapagos. The trial will utilize the uza-cel engineered T-cell Receptor (TCR) and Galapagos innovati

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_33 [2025-04-29 09:04:07 -0400] 790 Bytes | 187 tokens | Cum: 5987 tkns (74.84% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): ve decentralized cell therapy manufacturing platform. Uza-cel has shown encouraging results in head and neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmunes manufacturing platform.

Pre-Clinical Programs

Our preclinical pipeline is focused on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). We have implemented additional cost saving measures in relation to these programs.

Collaborations

We entered into ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADAP_OUT_35 [2025-04-29 09:04:16 -0400] 6301 Bytes | 1678 tokens | Cum: 7667 tkns (95.84% of 8k)
==========================================================================

This is our set of metrics for Adaptimmune Therapeutics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-------------------------+
| Volume: 418,365 | Perf Month: 25.95% | Option/Short: Yes / Yes | Sales Y/Y TTM: 194.23% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.68M | Perf Quarter: -52.14% | Short Float: 2.03% | ROE: -273.36% |
+-------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 0.25 | Index: - | Short Ratio: 2.74 | ROI: -86.30% |
+-------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 47.55 | Market Cap: 70.92M | Short Interest: 4.59M | Sales Surprise: -59.46% |
+-------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.03 | Shs Outstand: 255.94M | Beta: 2.82 | EPS Surprise: -61.95% |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA20: 10.36% | Shs Float: 226.52M | Sales Q/Q: 1269.96% | P/E: - |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -25.29% | Inst Own: 37.34% | Sales past 5Y: 193.37% | Earnings: Mar 20 BMO |
+-------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -62.37% | Insider Own: 11.49% | Employees: 506 | |
+-------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 14.41% | Insider Trans: -0.61% | Debt/Eq: 6.26 | |
+-------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading by Adaptimmune Therapeutics officers or majority shareholders (if available).

Inside Trans: Adaptimmune Therapeutics PLC (ADAP) by Bertrand William C JR (Chief Operating Officer) on 2025-02-20
- Option to purchase Ordinary Shares: 1612032 shares at $0 (D)
- Option to purchase Ordinary Shares: 1074696 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 178032000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -70814000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.2771
Average Volume: 1822906.15
30-Day High: 0.3239
30-Day Low: 0.197

[Detailed Financials: TTM 2024]
- Total Assets: $245,963,000.00
- Total Liabilities: $234,114,000.00
- Total Equity: $11,849,000.00
- Current Assets: $188,169,000.00
- Current Liabilities: $64,527,000.00

[Income Statement: TTM 2024]
- Revenue: $178,032,000.00
- Net Income: $-70,814,000.00
- Gross Profit: $177,962,000.00
- Operating Income: $-68,760,000.00
- Earnings Per Share (EPS): -0.05

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-53,811,000.00

[Detailed Financials: FY 2024]
- Total Assets: $245,963,000.00
- Total Liabilities: $234,114,000.00
- Total Equity: $11,849,000.00
- Current Assets: $188,169,000.00
- Current Liabilities: $64,527,000.00

[Income Statement: FY 2024]
- Revenue: $178,032,000.00
- Net Income: $-70,814,000.00
- Gross Profit: $177,962,000.00
- Operating Income: $-68,760,000.00
- Earnings Per Share (EPS): -0.05

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-53,811,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Adaptimmune Therapeutics (ADAP).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Adaptimmune Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because ADAP is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ADAP.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ADAP could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ADAP to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Adaptimmune Therapeutics.

11) ETHICAL_RATING[]
Rate Adaptimmune Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Adaptimmune Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ADAP_IN_37 [2025-04-29 09:04:16 -0400] 126 Bytes | 29 tokens | Cum: 7908 tkns (98.85% of 8k)
==========================================================================

====================================
[2025-04-29 09:04:16] # Analysis Completed
Elapsed Time: 24.46 seconds